SpringWorks Therapeutics Q3 2022 Earnings Report
Key Takeaways
SpringWorks Therapeutics presented positive data from its Phase 3 DeFi trial of nirogacestat, expanded collaboration with GSK, and initiated a new Phase 2 trial of nirogacestat. They also strengthened their financial position, providing sufficient runway into 2026.
Presented positive data from Phase 3 DeFi trial of nirogacestat in patients with desmoid tumors at ESMO Congress 2022.
Expanded global, non-exclusive collaboration with GSK to continue evaluating nirogacestat in combination with belantamab mafodotin in patients with multiple myeloma.
Dosed first patient in Phase 2 trial evaluating nirogacestat in patients with ovarian granulosa cell tumors.
Strengthened financial position to over $650 million in cash, cash equivalents and marketable securities.
SpringWorks Therapeutics
SpringWorks Therapeutics
Forward Guidance
This presentation contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995.